Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TRABECTEDIN for Leiomyosarcoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 142 adverse event reports in the FDA FAERS database where TRABECTEDIN was used for Leiomyosarcoma.

Most Reported Side Effects for TRABECTEDIN

Side Effect Reports % Deaths Hosp.
Neutropenia 207 10.6% 26 53
Anaemia 189 9.7% 22 79
Thrombocytopenia 172 8.8% 20 62
Nausea 160 8.2% 16 49
Febrile neutropenia 142 7.3% 21 89
Pancytopenia 124 6.3% 26 74
Vomiting 121 6.2% 19 49
Rhabdomyolysis 117 6.0% 51 80
Off label use 105 5.4% 29 16
Alanine aminotransferase increased 104 5.3% 13 53
Disease progression 103 5.3% 28 15
Acute kidney injury 92 4.7% 43 66
Aspartate aminotransferase increased 91 4.7% 12 49
Asthenia 90 4.6% 10 32
Pyrexia 89 4.6% 8 71

Other Indications for TRABECTEDIN

Ovarian cancer (275) Product used for unknown indication (227) Soft tissue sarcoma (183) Ovarian cancer recurrent (120) Uterine leiomyosarcoma (84) Leiomyosarcoma metastatic (79) Sarcoma (75) Myxoid liposarcoma (69) Liposarcoma (59) Sarcoma metastatic (53)

Other Drugs Used for Leiomyosarcoma

DOXORUBICIN (185) PAZOPANIB (132) GEMCITABINE (99) DOCETAXEL (89) IFOSFAMIDE (57) ERIBULIN (50) NIVOLUMAB (44) DACARBAZINE (42) GEMCITABINE\GEMCITABINE (42) OLARATUMAB (33)

Related Pages

TRABECTEDIN Full Profile All Leiomyosarcoma Drugs TRABECTEDIN Demographics TRABECTEDIN Timeline